ERNA · Ernexa Therapeutics Inc.
$3.93
-0.06 (-1.50%)
At close · Jul 24
Market Cap
$4.58M
Shares
1.17M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.93
Open$4.08
Day$3.91–4.20
52W$3.18–71.50
Avg vol 30d937K
Short int15K · 1.3% float · 1.0d
Short vol51%
Last earningsAug 7, 2020
DataJan 2020–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−78%
below
Price vs 50-day avg
−49%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−47%
trailing
6-month return
−87%
trailing
YTD return
−87%
this year
Relative strength
−93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $18 — 200d above 50d
Institutional flow
Distributing
4 of 20 funds reported for Jun 30 · net -38 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.26% of float · ▼ -49.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 1-yr high, broad support
Squeeze score
40
elevated · 0–100
Fundamentals
Revenue growth
+756%
Y/Y
Gross margin
84%
expanding
EPS growth
+95%
Y/Y
Free cash flow
$-7.1M
Balance sheet
$303.0K
net debt
Quant / Vol
risk profile
Volatility
155%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
22.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−78%
Bearish
Price vs 50-day avg
−49%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $18 — 200d above 50d
Institutional flow
Distributing
4 of 20 funds reported for Jun 30 · net -38 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.26% of float · ▼ -49.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $4 · 1%
52-wk high $72
vs 200-day avg -78%
vs 50-day avg -49%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERNA
this stock
Ernexa Therapeutics Inc.
|
$4.58M | -86.9% | +755.9% | — | 1.3% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERNA | -38.8% | -46.9% | -87.1% | -40.9% | -86.9% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -37.1% | -47.6% | -93.5% | -39.8% | -95.2% |